Side Effects of Weight Loss Injections Like Ozempic: What the Evidence Actually Shows

The biggest misconception: Ozempic side effects aren't the same as Wegovy side effects

Most people searching for Ozempic side effects are actually asking about semaglutide used for weight loss. The correction is important. Ozempic is semaglutide, yes, but it is licensed in the UK for type 2 diabetes and is given at lower maintenance doses than Wegovy. The side-effect profiles overlap significantly, because the mechanism is identical, but Wegovy's 2.4mg weekly maintenance dose (rising to 7.2mg with the newer pen approved by the MHRA in April 2026) produces more pronounced GI effects in trials than the doses typically used in diabetes management. Conflating the two leads people either to underestimate what they might feel at weight-loss doses, or to worry about diabetes-specific effects that don't apply to them at all.

The NHS medicines page for semaglutide covers both uses and is worth reading in full if you want the complete picture from a UK clinical source. For weight management specifically, the evidence that most UK prescribers work from comes from the STEP 1 trial, which ran for 68 weeks at 2.4mg and remains the reference point for licensed weight-loss treatment. You can read more about how Ozempic differs from weight-loss semaglutide in practice.

The short version: if your goal is weight management, the relevant medicine is Wegovy, not Ozempic. Understanding that shapes which side-effect information is actually relevant to you.

What the gastrointestinal side effects feel like, and when they tend to ease

Nausea is the most frequently reported side effect, affecting a substantial proportion of participants in semaglutide weight-loss trials. It is most noticeable in two windows: the first few weeks of treatment, and the days after each dose increase. For most people it peaks around 48 hours post-injection and then subsides. Vomiting is less common than nausea but does occur, particularly early on. Diarrhoea and constipation can alternate, and some people report a persistent feeling of fullness or slowed digestion, which is, mechanistically, part of how the medicine reduces appetite, but can feel uncomfortable.

Indigestion, acid reflux and burping are also listed among common effects, as is fatigue in the first few weeks. Headaches and dizziness appear occasionally. Injection-site reactions (redness, mild bruising, a small lump) resolve on their own and are less common with good technique: rotating between your abdomen, thigh and upper arm, and using a clean, dry site each time. Alcohol swabs are a simple way to keep the site clean before injecting.

The GI effects do ease for most people, which is one reason the titration schedule starts low and moves slowly. Rushing the dose increase is the single most common reason side effects become hard to tolerate. Your prescriber sets the pace, the schedule in the Patient Information Leaflet exists precisely to reduce this.

When you should contact a doctor or get urgent help

Most side effects are unpleasant but not dangerous. A few signals warrant prompt action. Severe stomach pain that persists and spreads to your back (with or without vomiting) can indicate acute pancreatitis, which is a serious condition. On 29 January 2026, the MHRA issued a Drug Safety Update specifically flagging this risk for GLP-1 medicines, describing it as infrequent but clinically significant. Stop the injection and seek urgent medical attention if this happens.

Other situations that need prompt medical review: signs of a severe allergic reaction (swelling of the face or throat, difficulty breathing, rapid heartbeat), symptoms of significant dehydration following severe vomiting or diarrhoea, and, in people with diabetes, signs of retinal changes or vision disturbance. Gallbladder symptoms (upper-right abdominal pain, especially after eating) are also documented with GLP-1 medicines and should be checked.

Low mood or thoughts of self-harm have been reported and should always be taken seriously; tell your prescriber or GP if you notice any change in your mental state. Never dismiss a side effect as minor if it feels wrong. Our prescribers are reachable through aftercare support seven days a week, and the Yellow Card scheme lets you report anything directly to the MHRA.

What is actually licensed for weight loss in the UK, and how to get there safely

Ozempic is not prescribed by UK clinicians for weight management; it is not licensed for that use here, and you should be cautious about any seller offering it for that purpose. The two medicines licensed in the UK for weight management are Wegovy (semaglutide injection, by Novo Nordisk) and Mounjaro (tirzepatide, by Eli Lilly). Both require a prescription following a clinical assessment. Wegovy shares the same active ingredient as Ozempic but with a weight-specific licence, weight-specific dosing and a body of weight-management evidence behind it.

If you are researching how many injections are involved in a course of semaglutide for weight loss, the answer is specific to Wegovy's schedule, not Ozempic's. The NHS medicines page for semaglutide covers both uses and explains the distinction clearly.

At nume, a GPhC-registered Independent Prescriber reviews every consultation personally, a real clinician, on the same day. Side effects, your health history and any medicines you already take are all part of that conversation. It is worth having that conversation before starting, not after. Explore licensed weight-loss treatment options or read about what the side effects of weight loss injections look like in practice and about semaglutide injection side effects in more detail if you want to go deeper before deciding.